1 month ago
India Approves First Dengue Vaccine
India has approved its first dengue vaccine called QDENGA.
This vaccine is for people aged 4 to 60 years and does not require any pre-vaccination tests.
It protects against all four types of dengue virus.
The vaccine has been approved in many countries and is recommended by the World Health Organization.
Takeda, the company that made the vaccine, is working with an Indian company to produce more doses.
This is a big step in fighting dengue in India.
India approves its first dengue vaccine, QDENGA, for ages 4-60.
The vaccine does not require pre-vaccination testing.
QDENGA is approved in 43 countries and recommended by the WHO.
Takeda plans to expand production in India with Biological E.
Dengue cases in India have increased 11-fold over the past two decades.
- Who
- Takeda Biopharmaceuticals India Pvt Ltd
- What
- Approval of the first dengue vaccine, QDENGA, in India
- Where
- India
- When
- July 20, 2026
- Why
- To combat dengue, one of India's most widespread mosquito-borne diseases
Public Health Advocates
Skeptics
Vaccine Efficacy
Public Health Advocates
The vaccine provides strong protection against all four dengue serotypes and is backed by extensive clinical trials.
Skeptics
Some skeptics question the long-term efficacy and potential side effects of the vaccine.
Public Health Impact
Public Health Advocates
The vaccine is a significant step forward in preventing dengue, especially in endemic regions.
Skeptics
Critics argue that more research is needed to ensure the vaccine's safety and effectiveness in diverse populations.
Key facts
- Vaccine Name
- QDENGA
- Manufacturer
- Takeda Biopharmaceuticals India Pvt Ltd
- Approval Authority
- Drug Controller General of India (DCGI)
- Age Range
- 4 to 60 years
- Global Approvals
- 43 countries
- WHO Recommendation
- Recommended for dengue-endemic settings
- Manufacturing Partner
- Biological E
- Annual Production Target
- 50 million doses in India, 100 million globally by the end of the decade
Timeline
Bangladesh braces for dengue as monsoon warnings surge.
Same day, QDENGA vaccine approved in response.
India's multi-strain dengue threat spurs QDENGA's green light.
First dengue vaccine, QDENGA, OK'd for India, aged 4-60.
No pre-vaccination tests required.
Quotes
Dr Suresh F Shah
Founder and lead pediatrician, Sparsh Children’s Hospital
“"The approval marks a genuine shift in how we approach dengue in India. Until now, management has been limited to vector control and supportive care because we have no specific antiviral therapy."”
rediff.com
Takeda spokesperson
Company representative for Takeda Biopharmaceuticals
“"We are committed to supporting broad, equitable, timely and sustainable access at a cost that reflects the vaccine’s value and potential health, societal and economic benefits."”
rediff.com
Sources
QDENGA: India approves first dengue vaccine for people aged 4-60 years
Govt approves first dengue vaccine for ages 4 60 by Japanese drugmaker Takeda
India approves first dengue vaccine QDENGA for people aged 4-60 years
India’s first dengue vaccine approved: DCGI clears Takeda’s Qdenga for those aged 4 to 60
India Approves First Dengue Vaccine QDENGA For Ages 4-60, No Pre-Vaccination Tests Required
QDENGA approved as India’s first dengue vaccine: Two-dose shot cleared for ages 4-60
India approves first dengue vaccine QDENGA for people aged 4-60 years
India Approves First Dengue Vaccine QDENGA for Ages 4–60 Years
Explained: India's first dengue prevention vaccine and the success story of this sector since Covid-19
India approves first dengue vaccine: Who can get it, dosage and how much will it cost
DCGI clears Takeda's QDENGA, India's first-ever dengue vaccine: Full details inside
India approves first dengue vaccine amid rising disease burden










